New advances in the treatment of hepatitis C provide high levels of sustained viral response but their expense limits availability in publicly funded health systems. The aim of this review was to estimate the proportion of patients who will spontaneously clear HCV, to identify factors that are associated with clearance and to support better targeting of directly acting antivirals. We searched Ovid EMBASE, Ovid MEDLINE and PubMed from 1 January 1994 to 30 June 2015 for studies reporting hepatitis C spontaneous clearance and/or demographic, clinical and behavioural factors associated with clearance. We undertook meta-analyses to estimate the odds of clearance for each predictor. Forty-three studies met the inclusion criteria, representing 20 110 individuals, and 6 of these studies included sufficient data to estimate spontaneous clearance.
| INTRODUCTION
During the acute phase of infection, HCV may completely resolve without treatment (spontaneous clearance) which is confirmed by the disappearance of HCV RNA in the serum. The proportion of HCV spontaneous clearance varies between studies, but it is believed to range from 20% to 30%. Factors nominated as predictors of clearance include female sex, [1] [2] [3] [4] ethnicity, variation of immune responses 5, 6 and host genetics. 7, 8 Polymorphisms in the interleukin-28 (IL28B) gene region are recognized as the strongest genetic factor associated with clearance. [7] [8] [9] New DAA represent a major advancement in hepatitis C treatment with cure rates above 90% for all HCV genotypes, shorter duration of therapy, less toxicity and fewer side effects. 10 There is major potential to substantially reduce the future burden of HCV cases if treatment can be targeted effectively to high-risk individuals such as PWID to prevent onward transmission and the progression of disease within these individuals. However, DAA are expensive, ranging from $25 000
in Spain to $54 000 in the UK and $51 000-$84 000 in the USA for a 12-week course of treatment. 11 In England, for example, treatment with DAA is restricted to approximately 10 000 patients in [2016] [2017] due to the large numbers of potential patients and the very high aggregate cost of the treatments involved. 12 However, the major burden of HCV is in PWID who are often not in contact with treatment services, and under this policy, only patients who attend clinic are eligible for treatment. Knowledge of variation between population subgroups in terms of the natural history of infection and the prevalence of spontaneous clearance could inform policy decisions on the use of DAA.
A systematic review published in 2006 estimated that 26% of HCVinfected patients achieve spontaneous viral clearance. 1 However, the study population was very heterogeneous, and it is likely that a wide range of further studies have been published since this study was conducted. The aim of this review was to ascertain precise estimates of spontaneous viral clearance and establish factors which are associated with spontaneous clearance to inform policy regarding the use of antiviral agents for HCV.
| METHODS

| Search strategy and selection criteria
We considered any studies that reported the proportion of spontaneous clearance in hepatitis C-infected patients AND/OR investigated factors associated with clearance as eligible for inclusion in the analysis. We conducted a systematic search using Ovid EMBASE, Ovid MEDLINE and PubMed, using the terms "hepatitis C" or "HCV"
AND "natural history" or "clearance" or "vir* negativ*." We included studies that were published in English after January 1994 (5 years since HCV was discovered and when more sensitive testing was already available) up to June 2015. A protocol for this review can be accessed at http://www.crd.york.ac.uk/PROSPERO/ with registration number: CRD42015023499. We defined HCV clearance as the absence of HCV RNA in blood. In studies that included both treated and untreated individuals, we only included untreated individuals. We excluded case reports, reviews and studies in very specific groups (eg, patients with lichen planus). We only included adult patients.
| Estimation of spontaneous viral clearance for HCV
To estimate the proportion of patients who achieved HCV spontaneous viral clearance, we identified longitudinal cohort studies with a minimum of 1-year follow-up which reported the time of infection (estimated as the mid-point between the last negative HCV antibody test result and the first evidence of HCV infection) and measured HCV RNA at baseline. Patients achieved spontaneous clearance if they had at least 2 consecutive serum samples with undetectable HCV RNA after the estimated date of infection. To determine the minimum follow-up time required to estimate the proportion of patients achieving spontaneous clearance, we fitted a weighted regression line plotting the proportion of patients achieving spontaneous clearance over time.
| Identification of factors that associated with HCV spontaneous clearance
For the analysis of factors associated with HCV clearance, we included all studies irrespective of whether the time of infection was known.
Studies including cross-sectional and case-control designs were eligible for inclusion. We included studies in this analysis provided HCV RNA was measured at least once during follow-up and that the study included data from at least 40 patients and reported the association between spontaneous clearance and at least one demographic, clinical, behavioural or host genetic risk factor.
Two independent reviewers conducted an initial screening of publication titles and abstracts to identify publications for full-text review.
We included the most recent publication if results were reported in more than one article. If we identified articles where the same participants may have contributed data to multiple studies, we contacted the study author where possible to clarify the study population. For the full-text review, 2 independent researchers reviewed relevant articles against the predefined inclusion and exclusion criteria. We preserved the records of included and excluded publications for audit purposes, indicating reasons for any exclusion. We performed and reported this systematic review using the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) guideline.
We used a standardized data extraction form to record the relevant data fields for each study, including (i) study characteristics:
setting, study design, method of data analysis, duration of follow-up, 
| Statistical analysis
For the subset of studies in which the time of infection was known precisely, we estimated the proportion of patients achieving HCV clearance at 3, 6, 12 and 24 months following the initial infection.
To examine the relationship between demographic, clinical and behavioural factors and HCV spontaneous clearance, we calculated odds ratios comparing the risk of clearance in patients with each risk factor to the risk of clearance in patients who lacked each risk factor. We included demographic factors (gender, age and ethnicity), clinical factors (viral co-infection, HCV genotype and symptomatic infection) and behavioural factors (alcohol consumption and PWID).
We used meta-analysis to summarize the relationship between each risk factor and outcome. Odds ratios were calculated, and forest plots were generated using Comprehensive Meta-Analysis (CMA) version 3.0. For host genetic determinants, after we found predictors which have strongest association with HCV clearance, we performed meta-analysis to summarize the allele's frequency of those predictors among HCV patients with spontaneous clearance, HCV patients with persistent infection, healthy population and patients with HCV infection to see whether the alleles are common. And finally, we tabulate the odds ratio and alleles' frequency to identify which genetic determinants were both common and have highest impact on clearance.
We investigated heterogeneity using I 2 and assessed publication bias using a funnel plot of proportions of clearance against the study size.
If there was evidence of heterogeneity (I 2 > 50%), we used random effect models.
| RESULTS
After excluding duplicates, we retrieved 9357 publications from 3 databases. Four hundred and eighty-three publications met the criteria for full-text review. We identified 6 studies where the precise 
| HCV spontaneous clearance
We restricted our estimate of the proportion of patients achieving spontaneous clearance to 6 studies 3,13-17 which provided precise information on clearance at specific time intervals following the acute infection, representing a total of 998 subjects. 
| Host genetic factors associated with clearance
We included a total of 86 studies to assess host genetic factors associ- Figure 6 ).
| DISCUSSION
In this systematic review and meta-analysis of hepatitis C spontane- We could not undertake meta-regression to adjust for potential confounders due to lack of individual-level data.
Our results suggest that the HCV spontaneous clearance at 12 months is 36.1%, higher than previous estimates from a study 
56-58
We found that decreased clearance was associated with male sex, non-HBV co-infection, asymptomatic infection, nongenotype 1 and older age. There is a range of evidence suggesting sex hormones influence immunity. 59, 60 However, the mechanism and the data of Many studies have investigated the association between age at time of infection and HCV clearance with conflicting findings. Based on our subgroup analysis, older age appeared to be associated with F I G U R E 6 Odds ratio of HCV spontaneous clearance in relation to allele frequency lower clearance. This might be due to younger people having a more vigorous immune response to viral infection. 70 However, as most of HCV patients were asymptomatic, some studies could not clarify the true initial time of infection which might produce bias at estimating the age at time of infection.
Our analysis found that alcohol drinkers or people who had history of drinking excess alcohol appeared to have a lower clearance.
It has been recognized that alcohol consumption is associated with liver disease progression among chronic HCV patients and increases progression of HCV to cirrhosis and HCC. 71 The specific association between race and HCV clearance is not well understood and may be confounded by other factors such as prevalence of injecting drug user. Some studies have proposed differences in natural killer (NK) cell populations 75 and frequencies of HLA Class II alleles 76 may explain the dissimilarity of hepatitis C natural history, spontaneous clearance rate and response to antiviral treatment among racial groups. It is also indicated that ethnicity associated with IL28B polymorphism is believed as the strongest host genetic predictor of HCV clearance. 9, 77, 78 Again, more studies are needed to better explain the racial differences in HCV immunity.
Furthermore, in common with previous studies, we found several host genetic predictors of HCV spontaneous clearance. Polymorphism in the interleukin-28 (IL28B) gene regions, specifically from IL28B rs12979860, IL28B rs8099917 and IL28B rs8103142, was the strongest candidates. Patients with favourable IL28B rs12979860 genotype CC were found to have better response to HCV treatment. 79, 80 Further studies are required to investigate mechanisms of these SNPs and IL28B involvement in HCV spontaneous clearance.
Overall, this study confirms a proportion of spontaneous clearance following acute HCV infection of over 35% at 1 year postinfection. Risk factors analysis demonstrated significantly reduced rates in individuals with HIV co-infection, active injection drug use and excessive alcohol intake. These data provide support for a strategy of early treatment for high-risk groups who are less likely to achieve spontaneous clearance, may pose a higher risk of onward transmission and who may be more likely to be lost to follow-up. These groups also represent the major burden of HCV.
The European Association for the Study of the Liver (EASL) has recently made similar recommendations. 81 Considering the challenges to outreach these higher risk groups, active engagement with drug and alcohol liaison services is required to address addiction problems and reinforce harm minimization approaches such as safe injecting practices and use of condoms that will reduce the risk of transmission and re-infection. It also important to support adherence as irregular treatment may increase the risk of drug resistance.
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